Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Provided By GlobeNewswire
Last update: Aug 12, 2025
FDA Accepted the Company’s Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025
Milestone Strengthens Balance Sheet to Fully Commercialize CARDAMYST if Approved
Read more at globenewswire.com
